Stene prize

Stene Prize Every year EULAR and the Standing Committee of PARE offer the Edgar Stene Prize for the best essay on a previously determined topic. The winner receives a prize money of EUR 1,000 is awarded during the Opening Plenary Session at the Annual EULAR Congress and is invited to the congress dinner. In addtion, […]

EULAR Young PARE youth meeting

SAVE THE DATE  2nd EULAR Young PARE youth meeting  Friday 21 October – Sunday 23 October 2016 Corsendonke de Linde, Retie, Belgium This email serves for you to block the dates in your calendar, for when our 2nd EULAR Young PARE youth meeting will take place. The location is Corsendonke de Linde, Retie, Belgium.  Please share this email with […]

WLF – World Lupus Day overview

Here is an overview of the common World Lupus Day campaign compiled by the World Lupus Federation on the extent and spread of the joint World Lupus Day Campaign. Duane Peters, who has been coordinating the WLF campaign, has told us that the response received has been excellent, especially the results of social media efforts.  News about the […]

LUPUS EUROPE YOUTH – Facebook group

As part of our initiatives directed towards youth, trustee Jeanette Andersen, who is responsible for youth related work, has set up a LUPUS EUROPE YOUTH group on facebook. Here is what she has to say about the group. “A group for all young people (aged 18-35) with lupus in Europe. Whether you have a youth group […]

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons
5 days ago
LUPUS EUROPE

Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the The New England Journal of Medicine, which you can find in the "Info Centre" section of our website!

Don't forget to subscribe to be up to date!

www.lupus-europe.org/me-lupus/lupus-europe-info-centre/
... See MoreSee Less

Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the The New England Journal of Medicine, which you can find in the Info Centre section of our website! 

Dont forget to subscribe to be up to date!

https://www.lupus-europe.org/me-lupus/lupus-europe-info-centre/
7 days ago
LUPUS EUROPE

No matter what chronic illness you're living with, having a sense of community and knowing
that you're not alone is helps your daily health and is key to staying motivated.

Follow the community over at @ThisIsLivingToday for tips and advice on wellness, mindfulness and movement. Let’s fight the daily battle together.
... See MoreSee Less

1 week ago
LUPUS EUROPE

We have partnered with @ThisIsLivingToday, a community of people living with chronic conditions with the aim of sharing tips, advice and inspirational stories that help improve health. 🧡

Follow their page @ThisIsLivingToday and hear from individuals who are facing the same challenges you may be facing. Let’s work together and lift each other up.
... See MoreSee Less

We have partnered with @ThisIsLivingToday, a community of people living with chronic conditions with the aim of sharing tips, advice and inspirational stories that help improve health. 🧡

Follow their page @ThisIsLivingToday and hear from individuals who are facing the same challenges you may be facing. Let’s work together and lift each other up.
2 weeks ago
LUPUS EUROPE

Good news!!! Belimumab, a monoclonal antibody, has been approved by the FDA for the treatment of pediatric patients with active lupus nephritis on standard therapy.

Belimumab is the first treatment specifically approved for lupus in more than 50 years.

You can read more about it, plus the results of the phase II, in the link from MedPage Today 👇

www.medpagetoday.com/rheumatology/lupus/99927
... See MoreSee Less

Comment on Facebook

💜

Yes!!!!!!

nu hopen dat Nederland artsen dit overneemt🤔

So happy to hear this

Brilliant

View more comments